Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$175.64
-0.6%
$164.95
$140.68
$181.16
$423.01B0.418.97 million shs2.57 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$727.81
-0.9%
$750.34
$623.78
$969.65
$689.23B0.444.17 million shs1.97 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$727.81
-0.9%
$750.34
$623.78
$969.65
$689.23B0.444.17 million shs1.97 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$55.78
-1.2%
$61.43
$45.05
$139.74
$249.17B0.6311.76 million shs6.85 million shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
+0.03%-1.07%+6.32%+15.15%+8.43%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-0.05%+4.23%-9.07%+1.89%-23.04%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-0.05%+4.23%-9.07%+1.89%-23.04%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
+2.17%+4.03%-18.11%-18.68%-58.20%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
4.8738 of 5 stars
2.35.04.23.94.01.71.9
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.9985 of 5 stars
4.35.03.34.03.23.32.5
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.9985 of 5 stars
4.35.03.34.03.23.32.5
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
4.6346 of 5 stars
4.15.02.50.02.60.03.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.65
Moderate Buy$176.290.37% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.67
Moderate Buy$950.1730.55% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.67
Moderate Buy$950.1730.55% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.13
Hold$81.0045.21% Upside

Current Analyst Ratings Breakdown

Latest LLY, JNJ, NVO, and LLY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/27/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeReduce ➝ Hold$675.00 ➝ $700.00
8/27/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeReduce ➝ Hold$675.00 ➝ $700.00
8/27/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeModerate Sell ➝ Hold
8/27/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeModerate Sell ➝ Hold
8/22/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Dbs Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
8/21/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$185.00 ➝ $200.00
8/20/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeHold ➝ Strong Sell
8/19/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$105.00 ➝ $70.00
8/17/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Daiwa Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Neutral$700.00
8/17/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Daiwa Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Neutral$700.00
8/17/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Daiwa America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$88.82B4.76$13.06 per share13.45$32.58 per share5.39
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$45.04B15.29$14.07 per share51.71$19.39 per share37.54
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$45.04B15.29$14.07 per share51.71$19.39 per share37.54
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$42.12B5.91$3.93 per share14.19$5.73 per share9.74
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$14.07B$9.3518.7915.872.2525.00%32.49%13.00%10/21/2025 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$15.3047.6023.391.0325.91%92.72%16.89%10/29/2025 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$15.3047.6023.391.0325.91%92.72%16.89%10/29/2025 (Estimated)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$14.64B$3.6415.3311.971.9235.60%78.64%24.51%11/5/2025 (Estimated)

Latest LLY, JNJ, NVO, and LLY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.59$6.31+$0.72$6.29$14.40 billion$15.56 billion
8/7/2025Q2 2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.59$6.31+$0.72$6.29$14.40 billion$15.56 billion
8/6/2025Q2 2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.93$0.97+$0.04$0.91$77.51 billion$11.69 billion
7/16/2025Q2 2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.68$2.77+$0.09$2.29$22.85 billion$23.74 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$5.202.96%N/A55.61%64 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.82%N/A39.22%11 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.82%N/A39.22%11 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.821.47%N/A22.53%N/A

Latest LLY, JNJ, NVO, and LLY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/23/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.500.78%8/15/20258/15/20259/10/2025
6/23/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.500.78%8/15/20258/15/20259/10/2025
7/16/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.303.35%8/26/20258/26/20259/9/2025
8/6/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
semi-annual$0.41192.4%8/18/20258/18/20258/26/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.50
1.01
0.76
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.86
1.28
1.00
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.86
1.28
1.00
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.52
0.78
0.56

Institutional Ownership

CompanyInstitutional Ownership
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%

Insider Ownership

CompanyInsider Ownership
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
CompanyEmployeesShares OutstandingFree FloatOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
152,7002.41 billion2.40 billionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
39,000946.46 million945.23 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
39,000946.46 million945.23 millionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
54,4004.47 billion4.46 billionOptionable

Recent News About These Companies

Novo Nordisk A/S $NVO Shares Sold by Synovus Financial Corp
2 Dividend Stocks to Hold for the Next 10 Years
Novo Nordisk A/S (NYSE:NVO) Trading Down 2.7% - Here's Why
Growth Stocks Worth Watching - August 26th
Novo Holdings Announces Sale of KabaFusion

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Johnson & Johnson stock logo

Johnson & Johnson NYSE:JNJ

$175.64 -1.15 (-0.65%)
As of 02:57 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$727.81 -6.36 (-0.87%)
As of 02:57 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$727.81 -6.36 (-0.87%)
As of 02:57 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$55.78 -0.66 (-1.17%)
As of 02:57 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.